The announcement of filing a BLA for Deramiocel, a potential treatment for DMD cardiomyopathy, is a significant milestone for Capricor. The lack of approved therapies for this condition and the FDA's support for rare disease treatments enhance the potential for approval. The recent European expansion deal and positive analyst ratings further boost investor confidence, leading to a substantial increase in stock price.